If you have been told you have IBS-D, you are probably familiar with the routine: dietary advice, maybe a low-FODMAP trial, possibly loperamide for bad days, and the general sense that this is something you just have to manage. And for many people, that is a reasonable approach because IBS-D is a real condition with real treatments. But there is a problem. A meaningful percentage of people carrying an IBS-D diagnosis actually have something different: bile acid malabsorption. The symptoms look almost identical. The standard IBS workup will not catch it. And the treatment is specific, effective, and completely different from what most IBS-D patients are offered.
What is bile acid malabsorption?
To understand BAM, you need a quick overview of how bile acids work in normal digestion. Your liver produces bile acids and stores them in the gallbladder. When you eat, particularly fatty foods, bile acids are released into the small intestine to help break down and absorb fats. After doing their job, about 95 percent of those bile acids are reabsorbed in the terminal ileum (the last section of the small intestine) and recycled back to the liver. This is called the enterohepatic circulation, and it cycles roughly 6 to 8 times per day.
In bile acid malabsorption, this recycling process fails. Too many bile acids escape reabsorption and spill into the colon. Once there, they stimulate the colonic lining to secrete water and electrolytes and increase motility. The result is watery, urgent diarrhea, often with cramping, bloating, and an unpredictable urgency that can be genuinely life-disrupting (Walters, 2014).
The three types of BAM
BAM is traditionally classified into three types, and knowing which one you have matters for understanding why it developed and what else to monitor.
- Type 1 (ileal BAM) occurs when the terminal ileum is damaged or has been surgically removed. Common causes include Crohn's disease affecting the ileum and surgical resection. The reabsorption machinery is physically compromised.
- Type 2 (primary or idiopathic BAM) is the most common form and the one most often confused with IBS-D. In these patients, the ileum appears structurally normal, but bile acid reabsorption is still impaired. The leading hypothesis involves deficient production of fibroblast growth factor 19 (FGF19), a hormone produced by the ileum that normally signals the liver to reduce bile acid synthesis (Walters et al., 2009).
- Type 3 (secondary BAM) is associated with other gastrointestinal conditions that disrupt the enterohepatic circulation, including celiac disease, chronic pancreatitis, post-cholecystectomy states, small intestinal bacterial overgrowth, and radiation enteritis.
Type 2 is the category that causes the most diagnostic confusion. These patients have no obvious ileal disease, their colonoscopy is normal, their celiac antibodies are negative, and they get labeled with IBS-D. Without specific testing for bile acid malabsorption, the true diagnosis can be missed for years.
How common is BAM among IBS-D patients?
This is the statistic that should change clinical practice: systematic reviews consistently estimate that 25 to 30 percent of patients who meet criteria for IBS-D have abnormal bile acid absorption when tested with SeHCAT (Wedlake et al., 2009). Some studies put the figure even higher, above 30 percent (Slattery et al., 2015). These are not fringe estimates. They come from well-designed diagnostic studies across multiple countries.
Despite this, testing for BAM is remarkably uncommon in routine clinical practice, especially in the United States. A survey of gastroenterologists found that many do not routinely consider BAM in their IBS-D workup, and a significant proportion were unfamiliar with the available diagnostic options (Kurien et al., 2020). The result is a diagnostic delay that averages over 5 years in many healthcare systems (Bannaga et al., 2017).
â ī¸If you have had chronic watery diarrhea labeled as IBS-D and have not been tested for bile acid malabsorption, it is worth asking your gastroenterologist about it. This is especially true if your diarrhea worsens after fatty meals, occurs first thing in the morning, or has not responded to standard IBS treatments.
How is BAM diagnosed?
The gold standard test is SeHCAT (selenium homocholic acid taurine), a nuclear medicine test available in the UK, Europe, and several other countries. You swallow a capsule containing a radiolabeled synthetic bile acid, and a gamma camera measures how much is retained in your body after 7 days. A 7-day retention value below 15 percent suggests mild BAM, below 10 percent indicates moderate BAM, and below 5 percent indicates severe BAM (Wedlake et al., 2009). The test is straightforward, well validated, and has good sensitivity and specificity.
In the United States, SeHCAT is not FDA-approved and is not available. This is a significant gap. American clinicians have two main alternatives. The first is measuring serum 7-alpha-hydroxy-4-cholesten-3-one (C4), an intermediate in bile acid synthesis that is elevated when the liver is overproducing bile acids to compensate for malabsorption. C4 is a fasting blood test, and elevated levels correlate reasonably well with abnormal SeHCAT results (Brydon et al., 2009). However, C4 can be falsely elevated in liver disease and falsely low in patients on statins.
The second and more commonly used approach in the U.S. is a therapeutic trial: prescribing a bile acid sequestrant (usually cholestyramine) and seeing if symptoms improve. If dramatic improvement occurs within 1 to 2 weeks, that is considered strong indirect evidence of BAM. This is practical but imperfect, because adherence to cholestyramine is challenging due to its taste and texture, and a partial response can be hard to interpret.
Treatment: what works for BAM?
The primary treatment for BAM is bile acid sequestrants, which are resins that bind bile acids in the intestine and prevent them from reaching the colon. The three available options are cholestyramine (Questran), colestipol (Colestid), and colesevelam (Welchol).
Cholestyramine is the oldest and most studied. It comes as a powder that must be mixed with liquid, and many patients find the gritty texture unpleasant. Response rates are around 70 to 80 percent in patients with confirmed BAM (Wedlake et al., 2009). The main reasons for discontinuation are taste, bloating, and constipation rather than lack of efficacy. Dosing typically starts at 4 grams daily and can be titrated up to 12 to 16 grams per day in divided doses.
Colesevelam is a newer tablet formulation that is much easier to take. It produces fewer GI side effects and has better adherence rates, though direct comparative trials are limited. Many clinicians now prefer colesevelam as the first-line sequestrant simply because patients are more likely to take it consistently. The typical dose is 625 mg tablets, 1 to 3 tablets twice daily.
One important practical note: bile acid sequestrants can interfere with the absorption of other medications, including thyroid hormones, warfarin, and oral contraceptives. They should generally be taken at least 1 hour before or 4 hours after other medications. Your pharmacist can help you sort out timing.
âšī¸If cholestyramine's taste or texture is a barrier, ask your doctor about colesevelam. It comes in tablet form and is generally better tolerated. The goal is finding a sequestrant you can actually take consistently.
What helps with tracking symptoms and treatment response?
When starting a bile acid sequestrant trial, tracking your symptoms carefully during the first 2 to 4 weeks is important. You want to document stool frequency, consistency, urgency, and any new symptoms like constipation or bloating. This data helps you and your doctor determine whether the treatment is working and whether the dose needs adjustment. An app like GLP1Gut can make this process easier by giving you a structured way to log daily symptoms, meals, and medication timing so you have a clear picture to bring to follow-up appointments.
Pay particular attention to whether your worst symptoms, especially the urgency and watery stools, improve. Some bloating from the sequestrant itself is common and does not mean the treatment is failing.
Why does this diagnostic distinction matter so much?
The reason this matters is not academic. If you have BAM but are being treated for IBS-D, you are likely receiving therapies that do not address the actual problem. Antispasmodics will not bind bile acids. A low-FODMAP diet will not fix impaired ileal reabsorption. Loperamide might help with urgency but will not reduce the volume of bile acids reaching your colon. Meanwhile, the specific treatment that could resolve most of your symptoms, a bile acid sequestrant, is not being offered because the diagnosis was never considered.
There is also a quality of life dimension. Many people with undiagnosed BAM spend years modifying their diets, avoiding social situations, and feeling frustrated that nothing works. Receiving the correct diagnosis and starting appropriate treatment can produce rapid, sometimes dramatic improvement within days to weeks. That kind of response is uncommon in IBS-D generally, which is another reason a strong response to sequestrants is considered diagnostically informative.
Can you have both IBS-D and bile acid malabsorption at the same time?
Yes, and this is part of what makes the picture complicated. Some patients have genuine visceral hypersensitivity and gut-brain axis dysfunction (IBS) alongside bile acid malabsorption. In these cases, bile acid sequestrants may improve diarrhea but leave other symptoms like pain and bloating partially unresolved. Treating both components may be necessary.
Does having my gallbladder removed increase the risk of BAM?
Yes. Post-cholecystectomy diarrhea, which affects roughly 10 to 20 percent of people after gallbladder removal, is often caused by bile acid malabsorption (Type 3). Without the gallbladder acting as a reservoir, bile acids flow continuously into the intestine rather than being released in controlled pulses with meals. If you developed chronic diarrhea after gallbladder surgery, BAM is a strong possibility worth testing for.
Is BAM a lifelong condition?
It depends on the type. Type 1 BAM caused by ileal disease may improve if the underlying condition is treated. Type 3 BAM secondary to another condition may also be reversible. Type 2 (primary) BAM tends to be chronic and typically requires ongoing management with bile acid sequestrants, though some patients find they can reduce their dose over time.